** Cytokinetics' CYTK.O shares down 6.1% to $72.40 on Weds as co seeks equity following promising heart disease drug data

** CYTK's stock finished up nearly 17% at over 2-yr high of $77.09 on Tues after co said chemically known drug, aficamten, met dual goals of a late-stage study for non-obstructive hypertrophic cardiomyopathy (nHCM), a genetic heart condition

** The drug, under brand name Myqorzo, was approved last year to treat symptomatic obstructive hypertrophic cardiomyopathy, which causes excessive thickening of the heart muscle and obstructs blood flow to the body

** Subsequently, co late Tues announced $650 mln stock offering

** It plans to use net offering proceeds for the commercial launch of Myqorzo, advance its pipeline, and research and general corp purposes, per the prospectus

** Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies joint bookrunners

** South San Francisco, California-based CYTK has ~124.2 mln shares outstanding for $9.6 bln market cap as of Tues

** With the move on Weds, stock up 14% YTD

** 18 of 21 analysts rate the stock "strong buy" or "buy", 3 "hold"; median PT $101, per latest LSEG data